Literature DB >> 14748772

Comparison of motor fluctuations and L-dopa-induced dyskinesias in patients with familial and sporadic Parkinson's disease.

S Papapetropoulos1, A A Argyriou, J Ellul, E Chroni.   

Abstract

The aim of the present work was to study the characteristics of motor complications in a group of familial Parkinson's disease (fPD) patients in comparison with matched sporadic PD (sPD) patients. Fifty-one fPD and 51 sPD patients matched for age and disease duration, used as controls, were included in the study. The Unified Parkinson's Disease Rating Scale was completed during clinical examination and all patients were questioned about the characteristics of motor complications. The mean time from start of L-dopa therapy to the onset of motor fluctuations (MF) and L-dopa-induced dyskinesias (LID) as well as the mean time from symptom onset to the development of MF and LID was significantly shorter in the fPD group of patients. An analysis revealed a higher occurrence of MF and LID in fPD patients in the group with disease duration of 5 years or less. FPD may be associated with a higher prevalence and earlier onset of motor complications during the initial stages of the disease. Genetic factors may contribute to the specific characteristics of motor complications in fPD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14748772     DOI: 10.1046/j.1351-5101.2003.00727.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  6 in total

1.  Motor fluctuations and dyskinesias in advanced/end stage Parkinson's disease: a study from a population of brain donors.

Authors:  S Papapetropoulos; D C Mash
Journal:  J Neural Transm (Vienna)       Date:  2006-12-07       Impact factor: 3.575

2.  Late aging-associated increases in L-DOPA-induced dyskinesia are accompanied by heightened neuroinflammation in the hemi-parkinsonian rat.

Authors:  Kathryn Lanza; Amy E Perkins; Terrence Deak; Christopher Bishop
Journal:  Neurobiol Aging       Date:  2019-05-31       Impact factor: 4.673

3.  Polymorphisms of the dopamine metabolic and signaling pathways are associated with susceptibility to motor levodopa-induced complications (MLIC) in Parkinson's disease: a systematic review and meta-analysis.

Authors:  Gita Vita Soraya; Zulvikar Syambani Ulhaq; Syifaus Shodry; Muhammad A'raaf Sirojan Kusuma; Sarah Herawangsa; Maharani Oryza Sativa; Aridin Gustaf; Dzakky Avecienna Nur Faridwazdi; Shinta Wulandari Florentia; Neila Raisa; Andi Kurnia Bintang; Muhammad Akbar
Journal:  Neurol Sci       Date:  2022-01-25       Impact factor: 3.307

Review 4.  Cerebellum in levodopa-induced dyskinesias: the unusual suspect in the motor network.

Authors:  Asha Kishore; Traian Popa
Journal:  Front Neurol       Date:  2014-08-18       Impact factor: 4.003

5.  Neuromelanin or DaT-SPECT: which is the better marker for discriminating advanced Parkinson's disease?

Authors:  A Okuzumi; T Hatano; K Kamagata; M Hori; A Mori; Y Oji; D Taniguchi; K Daida; Y Shimo; N Yanagisawa; S Nojiri; S Aoki; N Hattori
Journal:  Eur J Neurol       Date:  2019-06-24       Impact factor: 6.089

6.  Clinical aspects of palliative care in advanced Parkinson's disease.

Authors:  Johan Lokk; Ahmad Delbari
Journal:  BMC Palliat Care       Date:  2012-10-25       Impact factor: 3.234

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.